FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

TardiMed Sciences LLC		 2. Date of Event Requiring Statement (MM/DD/YYYY)
1/28/2020 

 3. Issuer Name and Ticker or Trading Symbol

BioPharmX Corp [BPMX]
(Last)        (First)        (Middle)

50 TICE BOULEVARD, SUITE A26		 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          ___X___ 10% Owner
_____ Officer (give title below)        _____ Other (specify below)
(Street)

WOODCLIFF LAKE, NJ 07677      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		2. Amount of Securities Beneficially Owned
(Instr. 4)		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)		2. Date Exercisable and Expiration Date
(MM/DD/YYYY)		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Warrants (right to buy) 1/28/2020 7/28/2022 Common Stock, par value $0.001 per share 2255336 $0.01 I See Footnote (1)
Explanation of Responses:
(1) The reported securities are held by Timber Pharmaceuticals LLC, a Delaware limited liability company ("Timber"). TardiMed Sciences LLC, a Connecticut limited liability company (the "Reporting Person"), owns a 90% interest in Timber. The Reporting Person disclaims beneficial ownership of the BioPharmX Corporation common stock underlying the reported securities held by Timber except to the extent of its pecuniary interest therein.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
TardiMed Sciences LLC
50 TICE BOULEVARD, SUITE A26
WOODCLIFF LAKE, NJ 07677
X
Signatures
/s/ Michael Derby, Managing Partner of TardiMed Sciences LLC1/30/2020
**Signature of Reporting PersonDate
BioPharmX (AMEX:BPMX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024 Haga Click aquí para más Gráficas BioPharmX.
BioPharmX (AMEX:BPMX)
Gráfica de Acción Histórica
De May 2023 a May 2024 Haga Click aquí para más Gráficas BioPharmX.